ImpediMed

ImpediMed FCF Growth

The Year-over-Year Free Cash Flow Growth of ImpediMed (IPD.AX) as of Nov 11, 2026 is -28.55 %. In the previous year, Year-over-Year Free Cash Flow Growth was 25.17 % — a change of -213.42% (lower).

FCF Growth

-28.55 %

YoY

-213.42%

Last updated:

Year-over-Year Free Cash Flow Growth of ImpediMed is 2026 -28.55 % . Year-over-Year Free Cash Flow Growth of ImpediMed was 2025 25.17 % . It decreases by -213.42% lower compared to the previous year.

The ImpediMed FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2019
16.90 AUD
Jan 1, 2020
-8.95 AUD
Jan 1, 2021
26.49 AUD
Jan 1, 2022
-32.90 AUD
Jan 1, 2023
-15.36 AUD
Jan 1, 2024
13.27 AUD
Jan 1, 2025
25.17 AUD
Jan 1, 2026
-28.55 AUD
The ImpediMed FCF Growth history
YEARFCF GrowthYoY
-28.55 %-213.42%
25.17 %+89.65%
13.27 %-186.45%
-15.36 %-53.32%
-32.90 %-224.18%
26.49 %-395.87%
-8.95 %-152.98%
16.90 %+91.33%
8.83 %-159.06%
-14.96 %-86.01%
-106.92 %+80.19%
-59.34 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ImpediMed Stock analysis

What does ImpediMed do? ImpediMed Ltd is an Australian company specializing in medical devices and technologies. They were founded in 1999 and have their headquarters in Brisbane, Australia. The company is a leading provider of bioimpedance measurement devices for the diagnosis, monitoring, and treatment of lymphatic, cardiac, and other medical conditions. They have a wide range of products used in various medical fields, including oncology, lymphology, and cardiology. Their main business model is based on the development and marketing of their bioimpedance measurement devices. They also provide training and support for medical personnel to optimize the use of their devices. ImpediMed specializes in the diagnosis and treatment of lymphedema in the oncology sector, particularly using their highly precise L-Dex® device. They also analyze body composition in the cardiology sector to determine the risk of heart diseases and develop personalized treatment approaches. In recent years, ImpediMed has expanded into the European market, particularly in lymphedema diagnosis and treatment. Overall, ImpediMed Ltd is an innovative company that focuses on medical devices and technologies for the diagnosis and monitoring of cardiac and lymphatic diseases. They provide important diagnostic capabilities to medical professionals and continue to focus on growth and expansion. ImpediMed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImpediMed stock

Year-over-Year Free Cash Flow Growth of ImpediMed is -28.55 % in 2026.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth ImpediMed since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's ImpediMed historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — ImpediMed

All Key Metrics — ImpediMed